🧪 UPDATED DAILY FROM CLINICALTRIALS.GOVSynced Apr 1

Find Clinical Trials for Your Rare Disease

15+ recruiting trials across all rare diseases. Filter by phase, location, and condition.

ℹ
Clinical trial records are synced from ClinicalTrials.gov.
Report missing data
Clear

Showing 15 of 15 recruiting trials for “differentiated-thyroid-carcinoma”

Phase 3RecruitingNCT07383246 ↗

CTR-FAPI-guided Precision Surgery for Newly Diagnosed MTC

👨‍⚕️ Shaoyan Liu, MD, Chinese Academy of Medical Sciences📍 1 site📅 Started Aug 2025View details ↗
NARecruitingNCT07068542 ↗

Sacituzumab Tirumotecan Combined With Immunotherapy in Advanced Thyroid Cancer

👨‍⚕️ Minghua Ge, Zhejiang Provincial People's Hospital📍 1 site📅 Started Jul 2025View details ↗
NARecruitingNCT07138716 ↗

Research on the Application of 68Ga-DOTA-CCK-FS PET/CT in MTC

👨‍⚕️ Yaping LUO, Peking Union Medical College Hospital📍 1 site📅 Started May 2025View details ↗
Phase 3RecruitingNCT06860971 ↗

A Study of AL2846 Capsule Versus Placebo in the Treatment of Advanced Radioiodine-Refractory Differentiated Thyroid Carcinoma

🏥 Chia Tai Tianqing Pharmaceutical Group Co., Ltd.📍 35 sites📅 Started Apr 2025View details ↗
Enrolling by InvitationNCT06852144 ↗

PET-TC in Thyroid Evaluation

🏥 IRCCS Azienda Ospedaliero-Universitaria di Bologna📍 1 site📅 Started Oct 2024View details ↗
Phase 2RecruitingNCT06440850 ↗

Vemurafenib and Cobimetinib for the Treatment of Patients With High Risk Differentiated Thyroid Carcinoma With BRAFV600E Mutation

👨‍⚕️ Sasan Fazeli, City of Hope Medical Center📍 1 site📅 Started Jul 2024View details ↗
Phase 2RecruitingNCT06359847 ↗

Study of ST-1898 in Locally Advanced or Metastatic Radioiodine-Refractory Differentiated Thyroid Cancer

👨‍⚕️ Yansong Lin, Ph D, Peking Union Medical College Hospital📍 1 site📅 Started Nov 2023View details ↗
NARecruitingNCT06277180 ↗

68Ga-TCR-FAPI PET/CT Guided Precision Surgery for MTC

🏥 Cancer Institute and Hospital, Chinese Academy of Medical Sciences📍 1 site📅 Started Oct 2023View details ↗
RecruitingNCT05994365 ↗

Study of Anlotinib Hydrochloride Capsules in the Treatment of Locally Advanced or Metastatic Radioiodine-Refractory Differentiated Thyroid Carcinoma

🏥 Chia Tai Tianqing Pharmaceutical Group Co., Ltd.📍 3 sites📅 Started Aug 2023View details ↗
Phase 1RecruitingNCT06520319 ↗

Head-to-head Study of 68Ga-MGS5 Versus 68Ga-DOTATATE PET/CT in Patients With Medullary Thyroid Carcinoma

👨‍⚕️ Weibing Miao, First Affiliated Hospital of Fujian Medical University📍 1 site📅 Started Jun 2023View details ↗
Phase 4RecruitingNCT05830500 ↗

Study of Anlotinib in Patients With Advanced Medullary Thyroid Carcinoma

🏥 Chia Tai Tianqing Pharmaceutical Group Co., Ltd.📍 19 sites📅 Started Jun 2023View details ↗
RecruitingNCT04216732 ↗

Natural History of Medullary Thyroid Cancer to Inform Advanced Disease Management

👨‍⚕️ Elizabeth G Grubbs, M.D. Anderson Cancer Center📍 2 sites📅 Started Jan 2020View details ↗
NARecruitingNCT03892993 ↗

Patient Decision Aid in Supporting Decision-Making About When to Start or Stop New Drugs, Join Clinical Trials, or Continue Active Surveillance in Patients With Medullary Thyroid Cancer and Their Caregivers

👨‍⚕️ Elizabeth G Grubbs, MD, M.D. Anderson Cancer Center📍 1 site📅 Started Apr 2019View details ↗
RecruitingNCT01660984 ↗

Natural History Study of Children and Adults With Medullary Thyroid Cancer

👨‍⚕️ John W Glod, M.D., National Cancer Institute (NCI)📍 1 site📅 Started Jul 2012View details ↗
RecruitingNCT01109420 ↗

Clinical and Genetic Studies in Familial Non-medullary Thyroid Cancer

👨‍⚕️ Joanna Klubo-Gwiezdzinska, M.D., National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)📍 1 site📅 Started Aug 2010View details ↗

Get alerts when new trials open

Create a free account to follow conditions and receive trial notifications.

Create free account →